Navigation Links
Oxygen Biotherapeutics, Inc. Expands Board of Directors
Date:3/20/2009

COSTA MESA, Calif., March 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced the expansion of the company's board of directors with the addition of J. Melville Engle to the board.

Engle has over 27 years experience in leading both large and small companies. He has raised money on Wall Street, launched hundreds of products, and has a broad management and financial background, including six years at Dey LP, where he was the firm's president and CEO. Dey LP, a Napa, CA-based specialty pharmaceutical company, is focused on the development and commercialization of products for respiratory, allergy and other breathing disorders. Engle's background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc.

"I'm very pleased that Mel has agreed to join our board," said Chris J. Stern, company chairman and CEO. "He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte(R)-based products to the market. During his tenure at Dey, sales increased from $250 million to over $600 million. Our board and company will be stronger with his involvement."

"I'm excited about the promise of Oxycyte and what I can see as the potential for this company. I'm looking forward to working with Chris and the other board members to help bring that potential to reality," said Engle.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs a
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
3. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
4. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
5. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
6. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
11. BioLife Solutions Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 /CNW/ - A new national Labour Market ... and demographic profiles of new graduates entering the biotech ... Building Careers for New Grads in Biotech," is sponsored ... Pharmaceutical Companies (Rx&D) and features data collected from new ... subsidy program from 2013 to 2015. Among ...
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... , March 30, 2015 ... auf    Richmond Pharmacology ist das erste ... Amyloidose-Zentrum am Royal Free Hospital in ... zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten ... von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... leading China-based,biotechnology company focused on researching, developing, ... appointment of,Dr. David Chen to the newly ... Operating Officer, effective immediately. Dr. Chen most ...
... Genomas(R), a,biomedical company advancing DNA-guided medicine and personalized,healthcare, ... I-II Small,Business Innovation Research (SBIR) Grant totaling $1.2 ... Safety and Efficacy," was,awarded by the National Institute ... the most prescribed drugs in the world. Drugs ...
... 19 AdvanDx announced it received,Frost & ... Award in the,field of rapid in-vitro molecular ... on AdvanDx,s easy-to-use, molecular-based,PNA FISH(TM) diagnostics to ... days. The rapid PNA FISH results enable ...
Cached Biology Technology:3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer 2Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 3AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 4
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... the world have forced many species to the brink of ... causes that are still not fully understood, researchers conclude in ... factor is often missing the larger picture, they said, and ... consider the totality of causes or could even make ...
... - Call them the Jason Bournes of the bacteria world. ... bacteria avoid antibiotic treatments by essentially shutting down and hiding ... professor in the Artie McFerrin Department of Chemical Engineering at ... is explained in the online April edition of Nature ...
... a research paper titled "Expanding the Diversity of Mycobacteriophages: ... PLoS ONE , a peer-reviewed online journal published ... included 12 Washington University undergraduates who had participated as ... University in St. Louis. Phages are viruses that ...
Cached Biology News:Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3Phage hunting students publish in PLoS ONE 2Phage hunting students publish in PLoS ONE 3
sPLA2-XII Human, Rabbit Polyconal Antibody Anti-Human sPLA2-XII Antibody was raised in rabbits against Human sPLA2-XII His-Tagged Fusion Protein Antigen: The recombinant human protein sPLA-XII...
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: